Healthcare Industry News: La Jolla Pharmaceutical
News Release - October 15, 2013
La Jolla Pharmaceutical Company Announces Appointment of Two Additional Independent DirectorsSAN DIEGO, CA--(Healthcare Sales & Marketing Network) - La Jolla Pharmaceutical Company (OTCBB: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that it appointed Mr. Craig Johnson and Ms. Laura Douglass to the Company's Board of Directors. Mr. Johnson currently serves as a director and chair of the audit committee on the boards of Mirati Therapeutics and Adamis Pharmaceuticals Corporation and most recently served as a director for Ardea Biosciences, Inc. Ms. Douglass is the Chief Executive Officer of Next Generation Clinical Research, a clinical research organization she founded. In addition, the Company announced the appointment of existing independent director, Mr. Saiid Zarrabian, as Chairman of the Board. The company now has 3 independent directors, as required for listing on major stock exchanges.
"We are very pleased to welcome Laura and Craig to the Board of La Jolla. They each add tremendous experience and talent to the board as we continue to build La Jolla," said George Tidmarsh, MD, PhD, President and Chief Executive Officer of La Jolla. "Saiid has worked extensively with management to help advance our programs and we welcome his expanded role to ensure continued close, independent oversight of our operations."
Mr. Johnson serves on the boards of directors for a number of life science companies. He is currently a director for Mirati Therapeutics, Inc. and Adamis Pharmaceuticals Corporation. Mr. Johnson also served as a director for Ardea Biosciences, Inc., from 2008 until its sale to AstraZeneca PLC in 2012. He was Chief Financial Officer of PURE Bioscience, Inc. from 2011 to 2012, and Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. from 2010 to 2011. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President for a wholly owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. He held several positions at MitoKor, Inc. from 1994 to 2004, including Chief Financial Officer and Senior Vice President of Operations. Prior to 1994, Mr. Johnson held senior financial positions with several early-stage technology companies, and he also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received his B.B.A. in accounting from the University of Michigan-Dearborn.
Laura L. Douglass
Ms. Douglass has over 20 years of management experience of increasing responsibility in the biopharmaceutical industry across multiple disciplines including research & development and operations. In 1999, Ms. Douglass founded and currently serves as President & CEO of Next Generation Clinical Research, a contract research organization providing clinical trial management services for products in development including pharmaceuticals, biologics, medical devices and diagnostics. Next Generation specializes in critical care medicine, nephrology and drug safety. Ms. Douglass' career includes positions in pharmaceutical and major international contract research organizations including Director of Clinical Affairs for Bone Care International (now Genzyme) and Director of Clinical Operations for Corning Besselaar (now Covance). Ms. Douglass is also a Founder and Board Member of SB Bancorp, a financial holding company, and Settlers Bank, a WI chartered business bank. She additionally serves on the Board of Directors for Agrace Hospice. Ms. Douglass holds a nursing degree from the State University of New York at Albany with advanced training in pharmacology and business from the University of Wisconsin. She has obtained certification in adult education and is a licensed education provider for the CA State Board of Registered Nursing. In 2008, Ms. Douglass was the Recipient of the Rising Star Award by Wisconsin Biotechnology & Medical Device Association and was honored in 2008 and 2010 as a successful Bio-Entrepreneur by the national group, Women In Bio. Most recently she was named as Finalist for 2010 Enterprising Women of the Year Award in Enterprising Women Magazine.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501 is a product candidate for the treatment of hepatorenal syndrome. For more information on the Company please visit http://www.ljpc.com.
Source: La Jolla Pharmaceutical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.